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A infecção por rotavírus, diretamente relacionada à qualidade de vida da população, pode culminar 
na morte, principalmente de crianças. Esta revisão discute a prevalência e distribuição de genótipos 
de rotavírus, com foco na variação genotípica do vírus após a implementação de vacinas e a infecção 
cruzada entre espécies animais e humanas. Foi pesquisada a literatura publicada de janeiro de 2006 
a julho de 2017, utilizando o banco de dados Web of Knowledge e os termos de pesquisa “rotavirus”, 
“genotype”, “prevalence post vaccine”, e “emerging genotypes”. Observou-se que os genótipos 
predominantes mudaram em todos os continentes e que alguns genótipos ainda estão emergindo. 
Duas hipóteses para essa mudança global são a variabilidade genética do vírus e o surgimento de 
genótipos resistentes a vacinas. Além disso, o vírus pode facilmente infectar várias espécies de animais 
que não o ser humano, como evidenciado por relatos de infecção cruzada de cepas, que serviram de 
alerta para a geração de novos genótipos de vírus. As ações intersetoriais que abrangem não apenas 
o setor da saúde, mas também todo o setor socioeconômico, incluindo o governo, pesquisadores, 
professores, agentes de saúde e comunidades, contribuem para diminuir os gastos relacionados à 
saúde e reduzir a mortalidade causada pelo rotavírus, melhorando assim indicadores de saúde e 
promoção da saúde em todo o mundo.
Rotavirus and the emergence of new genotypes: a narrative review
Rotavirus infection, which is directly related to the population’s quality of life, can culminate 
in death, mainly of children. This review discusses the prevalence and distribution of rotavirus 
genotypes, focusing on the genotypic variation of the virus after vaccines were implemented and 
cross-infection between animal and human species took place. We conducted a search of the 
literature from January 2006 to July 2017 by using the Web of Knowledge database and the search 
terms “rotavirus”, “genotype”, “prevalence post vaccine”, and “emerging genotypes”. The predominant 
genotypes changed in all the continents, and some genotypes are still emerging. There are two 
hypotheses for this global change: the genetics of the virus is variable, and vaccine-resistant genotypes 
have emerged. In addition, the virus can easily infect several animal species other than humans, as 
evidenced by reports of cross-infection of strains, which have served as a warning that new virus 
genotypes have been generated. Inter-sectoral actions that encompass not only the health sector, but 
also all the socio-economic sector including the government, researchers, teachers, health agents, 
and communities have contributed to reduce the health-related costs and mortality due to rotavirus 
infection, thereby improving health indicators and promoting health worldwide.
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Introduction
Globally, diarrhea is still the second leading cause of death among children aged less than five years 
(preceded only by respiratory infections). In 2015, diarrhea accounted for approximately 800,000 
(~10.5%) global deaths (HUNGERFORD et al., 2016). Rotavirus infection does not occur in economically 
disadvantaged countries only. Cases of this infection have also been recorded in developed countries 
despite significant improvements in hygienic conditions and water quality (GRAY, 2011).
Vaccination against the human rotavirus has helped to immunize much of the world population, but 
prevalence and emergence of new serotypes have been verified over the last decades (Dóró et al., 2014).
In Brazil, the rotavirus vaccine was introduced in 2006, but 2,475 cases were still registered in 2007. 
Before the vaccine was introduced, the most common rotavirus serotypes were G9P[4] and G1P[8]. In 
the years 2007, 2008, and 2009, after the vaccine had been implemented, genotype G2 prevailed. Therefore, 
the introduction of the rotavirus vaccine has clearly contributed to modifying the circulating genotypes, 
which has also been verified in other countries Dóró et al., 2014.
Rotavirus infection can culminate in death and lead to significant hospitalization, treatment, and 
prevention expenses. According to Ayres (2002), conditions that affect the frequency of contact between 
a specific microorganism and the host population are subject to multiple variations related to changes in 
habits or the environment combined with the production of knowledge in the field of infectious diseases. 
In light of the fact that health surveillance should assess the vulnerability of different populations and 
populations at risk so that the relevant technologies for protection and health promotion can be combined, 
this review aims to provide a narrative overview of rotavirus infection, focusing on the genotypic variation 
of the virus after vaccines were implemented. Additionally, we report cross-infection between animal 
and human species. 
The virus
It was in 1973 that the rotavirus was first described as a gastrointestinal agent in humans. This wheel-
-shaped virus was detected in biopsies of duodenal mucosa obtained from children with acute gastroen-
teritis (DAVIDSON; BARNES, 1979). Its shape is the reason for its name, rotavirus, derived from the 
Latin word ‘’route’’, which means wheel.
The rotavirus is a double-stranded RNA virus belonging to the Reoviridae family. The complete particle 
consists of a triple-layered capsid protein that involves 11 RNA segments of different sizes, ranging 
from 667 (segment 11) to 3,302 base pairs (Segment 1), amounting to RNA with 18,680 base pairs 
(RIXON, TAYLO, DESSELBERGER, 1984). The rotavirus RNA encodes six capsid proteins (VP1–VP4, 
VP6, and VP7) and six non-structural proteins (NSP1-NSP6), which account for functions that are 
essential to the replication, pathogenesis, and determination of the specificity of the species (SALGADO; 
UPADHYAYULA; HARRISON, 2017). The virus also produces particles with double layer protein or just 
a protein layer (“core”) involving the genome (PRASAD et al., 1988).
Development
Rotavirus classification
The rotavirus was initially classified into six serogroups: Rotavirus A (RVA), Rotavirus B (RVB), Ro-
tavirus C (RVC), Rotavirus D (RVD), Rotavirus E (RVE), and Rotavirus F (RVF), on the basis of virus 
capsular antigens detected by serological reactions (EESTES; KAPIKIAN, 2007). Groups A–C can be 
identified in both humans and animals, whereas groups D-F occur exclusively in animals. The rotavirus 
belonging to Group A causes over 95% of human infections around the world, whereas the rotavirus be-
longing to Group B underlies large outbreaks of gastroenteritis in children and adults in China. Despite 
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its worldwide distribution, the rotavirus belonging to Group C has low prevalence Costa et al., 2004.
Antibody neutralization reactions that use antisera obtained from animals previously immunized with 
proteins VP4 or VP7, located on the outer side of the rotavirus capsid, have also helped to classify the 
virus into serotypes G, defined by epitopes on glycoprotein VP7, and serotypes P, related to the protease-
sensitive protein VP4 (KAPIKIAN, 2007; COSTA et al., 2004). Nine antigenic types of VP7 (protein with 
greater expression in the external capsid of the virus and with greater capacity to induce the formation 
of antibodies) have been described, four of which have been detected in humans. Serotypes G are the 
most frequent in the world, and serotype G1 prevails in Argentina, Brazil, Chile, Costa Rica, Ecuador, 
Honduras, Mexico, Panama, and Venezuela Dóró et al., 2014.
A classification system based on the analysis of genome nucleotide has also been proposed for RVA. 
This system assigns a specific genotype for each of the 11 RNA segments of the virus. Comparison of the 
individual sequences of RNA segments of the rotavirus belonging to Group A to the individual sequen-
ces of RNA segments of other viruses has shown that RVA resembles influenza viruses. Substitutions or 
rearrangements of bases between different RNA segments occur, and many of these mutations take place 
mainly in segment 11, which codes for two Non-structural proteins, NSP5 and NSP6 (GIAMBIAGI et 
al., 1994; SCHNEPF et al., 2008). Such mutations often alter the conformation of protein VP6, present 
in the intermediate capsid, and are the basis for the classification of subgroups I and II. Most importantly, 
chronic infection in immunodeficient children has been suggested to favor the rearrangement of RVA 
strains, which allows the virus to replicate for long periods Troupin et al., 2011.
The current rotavirus nomenclature designates each RNA fragment, VP7-VP4-VP6-VP1-VP2-VP3 
and NSP1 to NSP5/6, by letters, Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx, where “x” represents the arabic 
number starting from 1 (CARVALHO-COSTA, 2019).
From 2007 to 2012, identification of the genotypes revealed that 46,967 rotavirus strains belonging to 
Group A existed in 81 countries. Of this total number of strains, 8,224 were characterized in Africa, 2,341 
in the Eastern Mediterranean region, 6,756 in the Americas, 14,438 in Europe, 5,728 in Southeastern Asia, 
and 9,480 in the Western Pacific region Dóró et al., 2014.
The rotavirus genotype has been reclassified by methodologies based on the sequencing of gene VP6 
and metagenomic studies, which has allowed eight rotavirus groups to be designated as distinct species 
A–H Matthijnssens et al., 2012. Rotavirus A prevails in mammals and birds; Rotavirus B, Rotavirus C, 
Rotavirus E, and Rotavirus H occur in mammals; Rotavirus D, Rotavirus F, and Rotavirus G emerge in 
birds only; and Rotavirus I (RVI) has been described in dogs Trojnar et al., 2013.
Survival and transmission 
The gastrointestinal tract and feces of infected humans are the reservoir of the rotavirus. The virus 
primarily replicates in the small intestine, particularly in the jejunum, a process that involves the top cells 
of the intestinal villi.
The rotavirus can be transmitted by fecal-oral dissemination or through person-to-person contact. 
About 10 particles of the virus are excreted per gram of feces, and the maximum viral excretion occurs 
on the third and fourth days since the onset of the first symptoms. During the acute phase of the disease, 
viral elimination may begin two days before the onset of diarrhea and may persist for 10 days after the 
onset of the symptoms. If we consider immunodeficient individuals, the virus can be detected for over 
30 days after infection (GRAY, 2011; DENNEHY, 2012). Only 10 to 100 viral particles are necessary to 
infect humans, increasing the potential risk of infection and making epidemics common (GRAY, 2011).
Other sources of the virus such as airway secretions, objects, surfaces, toys, water, and food have been 
pointed out in most emissions from pre-schools and schools. In addition, because the rotavirus can 
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survive for weeks or even months on non-disinfected surfaces, it is also an important cause of nosocomial 
diarrhea (DENNEHY, 2012).
The rotavirus can recognize different cell receptors, but carbohydrates of the cell surface, which are 
evolutionarily conserved in humans and some animals, are probably the main receptors for the rotavirus 
(LIU et al., 2016b). Other binding sites including sialic acid (CIARLET et al., 2002), heat shock proteins 
(Zárate et al., 2003), and integrins (GRAHAM et al., 2003), may allow the virus to penetrate into the host 
cell. Zoonotic transmission of rotavirus genotypes (Table 1) resulting from intimate contact between 
humans and animals or from contamination of water or food reservoirs by excreta from infected animals 
has been reported (DHAMA et al., 2009; MARTELLA et al., 2010; TSUGAWA; HOSHINO, 2008; 
GUERRA et al., 2016; NGUYEN et al., 2016; MARTON et al., 2017; KOMOTO et al., 2016). This reveals 
that there are natural sources of viral genomes where mutations and creation of new viral genotypes of 
unpredictable virulence take place.










Humans Dhama et al., 2009; Martella et al, 2010
G3P[3] (Ro1845 
and HCR 3A)
Canine or feline Humans Tsugawa and Hoshino, 2008
G3P[8] Equine Humans Guerra et al., 2016
G3P[9] Feline Humans Nguyen et al., 2016
G4, G5, G6 e G8 Swine
Humans, calves 
and camels.
Dhama et al., 2009; Martella et al., 2010
G5 Swine and equine Humans Dhama et al., 2009; Martella et al., 2010
G6, G8, and G10 Bovine Humans Dhama et al., 2009; Martella et al., 2010
G8P[14] Bovine or ovine Humans Marton et al., 2017
G9 Swine and lambs Humans Dhama et al., 2009; Martella et al., 2010
NSP2 Bovine Humans Komoto et al., 2016
Source: Prepared by the authors.
Clinical manifestations and physiopathology of the disease
Rotavirus infection usually begins with low-grade, acute fever and vomiting. After 24 to 48 hours, 
watery diarrhea (10 to 20 evacuations/day) starts, and symptoms may persist from three to eight days. 
Dehydration and electrolyte disturbances are the main and most frequent sequelae of rotavirus infection 
(DENNEHY, 2012).
The rotavirus represents the main etiological agent of severe gastroenteritis among infants and children 
aged less than five years worldwide. The aggravating effects of the disease have been related to complica-
tions such as necrotizing enterocolitis, intussusception, and biliary atresia, which contribute to episodes 
of prolonged diarrhea and intolerance to carbohydrates and lactose in some children. Other systemic 
infections, viremias, and even aggravation of autoimmune diseases can happen in patients infected with 
the virus (DENNEHY, 2012).
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When humans ingest food and water contaminated with the virus, protein VP4 on the external surface 
of the rotavirus is fractionated by the enzymes pancreatin, trypsin, or elastase into two smaller proteins 
(VP5 and VP8). Subsequently, the virus adheres to and infects enterocytes, destroying enzymes like 
maltase, sucrose, and lactase. This destruction prevents disaccharides from breaking and being absorbed, 
thereby increasing the osmolarity of the intestinal lumen and raising the influx of liquid (LIU et al., 2016b). 
Furthermore, intestinal bacteria may act on unabsorbed sugar, which results in elimination of feces with 
acid pH and may accentuate the diarrhea of osmotic nature. The viral enterotoxin (protein NSP4, which 
resembles the cholera toxin) also decreases the activity of Na/K ATPase, which underlies the intestinal 
absorption of sodium coupled to glucose, reducing the absorption of sodium and water. Activation of 
the enteric nervous system by infection can also induce diarrhea, to culminate in secretion of intestinal 
fluid, electrolyte liquid, and thus diarrhea (LUNDGREN, 2000; BALL et al., 1996).
Epidemiology
Almost all children aged five years are estimated to have had an episode of rotavirus gastroenteritis. 
This virus accounts for about 5% of infant mortality per year worldwide. About two million admissions 
and over 500,000 thousand deaths are attributed to this virus every year (GRAY, 2011).
Liu et al. (2016a) reported that children’s first exposure to a rotavirus infection during the first six 
months of life often results in severe illness that requires hospitalization. Interestingly, the number of 
hospitalizations decreases among infants aged less than three months probably because they receive 
passive maternal antibodies through breastfeeding.
Rotavirus infection involving older children and adults was related to outbreaks or to population 
groups that are at risk of contracting the infection such as travelers to endemic areas, individuals working 
in enclosed spaces like day care centers and hospitals, individuals who may be in contact with sick chil-
dren, the elderly, and immunocompromised patients. Between 30 and 50% of the adults that come into 
contact with infected infants become infected, as well (Ford-Jones et al., 2000). However, the disease is 
asymptomatic in most of these adults because they present neutralizing antibodies previously acquired 
during natural primary and/or secondary infections (LUCHS; TIMENETSKY, 2016).
The seasonality of rotavirus outbreaks is more evident in countries with temperate climate and is less 
visible in countries with tropical climates. Patel et al. (2013) reported that the level of development of 
a country influences the intensity of the disease more than season, latitude, or geographical location. 
In African, Asian, and South American countries, where seasonal variation is smaller, incidence of the 
rotavirus is high as compared to more developed countries in Europe, North America, and Oceania.
In the United States, the rotavirus is estimated to cause 20 to 60 deaths, 55,000 to 70,000 hospitalizations, 
205,000 to 272,000 visits to emergency units, and 410,000 outpatient consultations annually, with total 
expenditures estimated at one billion dollars (Fischer et al., 2007). Fischer et al. (2007) reported that 
American children infected with the virus develop episodes of gastroenteritis, which often leads parents 
to skip work to provide care for their sick children. In Brazil, the rotavirus was first recorded in 1976, 
when the virus was the main cause of severe diarrhea in children aged less than five years. If we consider 
the average positivity indexes by region, the northern region stood out with an index of 36.5% up to the 
year 2000 (LINHARES; BRESEE, 2000). By 2006, about 2,500 children under the age of five had died each 
year (MASUKAWA et al., 2014).
In recent years, the rotavirus disease has developed differently across continents. Steele et al. (2016) 
reported that the incidence of the rotavirus in unvaccinated children aged between two and six months is 
approximately twice as high in Africa as compared to Europe; an opposite trend emerges during the second 
year of life. According to these authors, the natural immunity rate to the wild-type infection acquired at 
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a younger age is higher in unvaccinated children from low- to middle-income nations as compared to 
children living in high-income countries.
In the United Kingdom, the rotavirus accounts for 45% of hospitalizations for acute gastroenteritis and 
for 20% of emergency care (HUNGERFORD et al., 2016). In China, the total annual expenditure on the 
treatment of cases of rotavirus gastroenteritis is USD 365 million, with the virus underlying 18.4–54.0% 
of cases of acute diarrhea in children aged less than five years (LIU et al., 2016a).
Prevention of infection and post-vaccine impact
Before the rotavirus vaccine was introduced, rotavirus infection was primarily treated with oral rehydra-
tion and adequate feeding of liquids; the adjuvant action of selected probiotics has also been reported. 
Additionally, frequent hand hygiene has been described as one of the most important procedures to mi-
nimize transmission of the rotavirus (DENNEHY, 2012). However, disinfectants such as chlorhexidine 
are ineffective against the virus, and soap and water do not remove all the viral load; in contrast, agents 
containing alcohol are more effective against the virus.
Vaccination is undoubtedly the major strategy to control rotavirus infection. The vaccine consists mainly 
of attenuated viral particles whose oral administration stimulates the individual’s immune system against 
the virus. The first human rotavirus vaccine (RotaShield, RRV-TV) was licensed in 1998. It was a tetra-
valent vaccine that contained four strains of the virus represented by the most commonly disseminated 
types G. Although the efficacy of the vaccine was between 80 and 100%, it was discontinued 14 months 
after its introduction because cases of intussusception associated with vaccination were reported (world 
rate of 1–10,000) (CENTERS FOR DISEASE CONTROL AND PREVENTION, 1999).
Subsequently, other vaccines were licensed and are currently in the market; e.g., RV5 (RotaTeq®), a live 
oral vaccine manufactured by Merck (three doses, at two, four, and six months of age) that was licensed 
in 2006; RV1 (Rotarix®), a live oral vaccine manufactured by Glaxo Smith Kline (two doses, at two and 
four months of age) that was licensed in 2008; and RIX4414 (RV1), licensed in 2006, which consists of 
attenuated virus of strain G1P, which is the most common in humans (DENNEHY, 2012).
The worrying data about the rotavirus have led the WHO to coordinate the Rotavirus Global Surveil-
lance Network since 2008. The Network advocates that rotavirus be tested in infants and children aged less 
than five years that are hospitalized for acute gastroenteritis. One of the original objectives of the Network 
was to provide data to describe the epidemiology of the disease, to establish a platform to measure the 
impact of vaccination, and to identify viral strains and their distribution (WHO, 2010).
Among the regions assessed by the WHO in 2009, the Americas had the lowest rate of rotavirus detec-
tion: 25%. In Brazil, immunization with the oral rotavirus vaccine, was licensed in 2005 and introduced 
into the national immunization program in 2006, under the trade name Rotarix®. In 2008, immunization 
in children reached a rate of 82% and has increased ever since. From its implementation in 2006 until 
2011, the vaccine prevented 1,804 deaths, 91,127 hospitalizations, and 550,198 outpatient visits each 
year, which reduced the general health costs related to rotavirus gastroenteritis by 76% (AMBROSINI; 
CARRARO, 2012; CARVALHO-COSTA et al., 2019).
By 2012, rotavirus vaccines had been licensed in 125 countries and had been included in the National 
Immunization Program of 29 (15%) out of 193 countries worldwide, mostly in Latin America (50%). 
However, by 2012 no low-income country had been included in the immunization program even though 
these countries represented a large proportion of cases of high-severity diseases caused by the rotavirus 
(DENNEHY, 2012). Fortunately, other 60 countries introduced either RV1 (monovalent vaccine) or RV5 
(pentavalent vaccine) in their child immunization programs in May 2014 (DÓRÓ et al., 2014).
One of the first African countries to introduce the rotavirus vaccine in its national immunization 
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program was Malawi in 2012, which lowered hospitalization costs related to the virus-infected population 
by 43% (NAKAGOMI et al., 2013). In other African countries, such as the Democratic Republic of 
Congo, Ethiopia, and Nigeria, vaccines have prevented from 28 to 31% of rotavirus-associated deaths 
(KOLLARITSCH et al., 2015).
In the US, Kaufman and Chen (2016) suggested that vaccination effectively diminished rotavirus 
infections among infants and children by reducing the rate of rotavirus positivity in the post-vaccine 
period by 73.3%.
Studies in Panama, Brazil, and Mexico reported a reduction of between 22 and 50% in deaths caused 
by diarrhea and estimated that the vaccine (RV1) prevents 1,800 deaths in Mexico and Brazil and nearly 
27,000 deaths in India per year. Concerning the European continent, the rate of hospitalization due to the 
rotavirus decreased by 60% in Germany. In Belgium, where vaccination coverage is high, vaccination is 
90% effective. In Austria, one of the first countries to implement vaccination in 2007, hospitalization due 
to rotavirus infection decreased by 70% as compared to the pre-vaccination period (2001-2006) (WHO, 
2010).
Overall, 85–98% of the different rotavirus vaccines available worldwide are effective: hospitalization, 
medical visits, mortality from acute gastroenteritis, and the number of positive laboratory results have 
decreased (WHO, 2010; GRAY, 2011; HUNGERFORD et al, 2016). Nevertheless, implementation of the 
vaccines has led to replacement of existing serotypes, so rotavirus infection still prevails in many countries 
despite the efficacy of rotavirus vaccines.
In Latin America (Table 2), serotype G2 has emerged after vaccination (LINHARES et al., 2011), but 
other genotypes also circulate in Latin American countries. In Argentina, strain G12P[8] emerged in 
2008, and strain G2P[4] re-emerged and became predominant again in 2011 (MANDILE et al., 2014). In 
Brazil (Table 2), introduction of the vaccine elicited replacement of genotypes G1P[8] and G9P[8] with 
genotype G2P[4] in several regions of the country (Carvalho-Costa et al., 2019). In the years 2012, 2013, 
and 2014, genotypes G3P[8] and G12P[8] reappeared throughout the country (AMBROSINI; CARRARO, 
2012; Dóró et al., 2014). In 2008, G9P[8] was the predominant rotavirus genotype in Cuba, Chile, and 
Bolivia (RIBAS et al., 2011; DÓRÓ et al., 2014). However, in Colombia and Paraguay, infections caused 
by genotype G2P[4] increased from 2008 to 2011 (MARTÍNEZ et al., 2010; PELÁEZ-CARVAJAL et al., 
2014). Vizzi et al. (2017) reported that genotype G1P[8] re-emerged after the vaccine was introduced in 
Venezuela and, together with genotype G2P[4], caused most of rotavirus infection in the country.
In North America, strains G1, G2, G3, G4, and G9 were commonly identified after the vaccine was 
implemented (MAST et al., 2010). In the United States, the most prevalent serotype was G3 a few years 
ago; G3P[9] was the most common line, and G12 and G14 were possibly emerging strains (DÓRÓ et 
al., 2014). The predominant genotype has now changed: the genotype with the highest prevalence is 
G12 (Bowen, 2014; Wylie, Weinstock and Storch, 2015). In Canada, genotypes G1P[8], G3P[6], G3P[8], 
G2P[4], G9P[8], G4P[8], and G9P[4] have been reported (CHETRIT et al., 2013).
The African continent has the highest rates of the rotavirus, which is understandable if we remember 
that the conditions in which the population lives, including health services and sanitation, among others, 
determines the occurrence of diseases with preventable causes. Between 2006 and 2016, types G (G1, G2, 
G3, G9, and G12) were the most common in Africa; G1 prevailed. Among types P, P[8] predominated 
especially in North Africa, followed by P[6] and P[4]. The combination G1P[8] was the most found, but 
G2P[4], G9P[8], and G2P[6] was also reported (OUERMI et al., 2017).
G12 is an emerging genotype in Cameroon, but a different sub-lineage predominates there (Table 
2) (DÓRÓ et al., 2014). G1P[8] prevails in Ghana (DÓRÓ et al., 2014), but Agbemabiese et al. (2016) 
pointed out the evolution of G2P[4] in the country. In Malawi, G12, sub-lineage G12P[6], has increased 
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progressively (Nakagomi et al., 2017). According to Motayo et al. (2016), G1, G8, and G9 are the common 
strains in Nigeria. Apart from genotype G1P[8], other strains also circulate in Kenya, where the dominant 
lineage is G9P[8] (DÓRÓ et al., 2014). Genotype G1P[8] is the most frequent in Tunisia, but G3P[8] also 
circulates in this country (DÓRÓ et al., 2014; MOUSSA et al., 2016).
In Asian countries (Table 2), the predominant strains are G1, G2, G3, and G9. In China, strain G1, and 
no longer G3, prevailed in 2011 (DÓRÓ et al., 2014). Zhang et al. (2017) reported that strains G1 and 
G2 nowadays circulate and predominate along with strain G9. According to Asada et al. (2016), in Japan 
strain G3 prevailed from when the vaccine was implemented until 2015 (DÓRÓ et al., 2014; FUJII et al., 
2019), but strains G1 and G2 are currently prevalent. In South Korea, the predominant strains are also 
G1 and G2 (CHUNG et al., 2015). In Thailand (DÓRÓ et al., 2014), the prevalent genotype is G1P[8] 
followed by G2P[4] and G3P[8]. Do et al. (2017) reported that strain G1 also prevails in Vietnam, where 
sub-lineage G1P[8] stands out (Table 2).
In the case of European/Eurasian countries (Table 2), G9P[8], G2P[4], G1P[8], and G4P[8] prevailed. In 
Austria, genotype G2P prevailed after the vaccine was implemented in 2007, but serotype G2P[4] emerged 
in 2011 (DÓRÓ et al., 2014). Furthermore, infection by genotype G2P[4] occurred in Belgium even after 
vaccine RV1 was implemented (PITZER et al., 2015). Genotypes G4P[8] and G1P[8] predominate in 
Greece, whereas genotype G9P[8] predominated in 2012 in Hungary (DÓRÓ et al., 2014; KOUKOU et 
al., 2015).
In India, genotype G1P[8] followed by genotype G9P[8] prevailed a few years ago (BABJI et al., 2018; 
GUPTA et al., 2019), but Chitambar et al. (2014) reported the emergence of G9P[4]. Pradhan et al. (2016) 
reported that G9P[4] is the most frequent genotype in India.
In countries like Ireland, Collins et al. (2015) indicated the prevalence of G1P[8] and reported changes 
in circulating patterns with the re-emergence of G2P[4]; in Italy, the predominant genotype is G1P[8] 
(DÓRÓ et al., 2014).
Based on the report by Anca et al. (2014), the predominant genotype in Romania has changed from 
G9P[8] and G4P[8] to G1P[8] since the vaccine was introduced. In Russia (LOBZIN et al., 2017), genotype 
G1P[8] also prevailed. In contrast, the prevalence of rotavirus genotype has changed from G1P[8] to 
G4P[8] along with G2P[4] in Slovenia (Steyer et al., 2014).
In Turkey, the rotavirus strains were classified into genotypes G1–G4 between 2000 and 2010, but 
recent studies have pointed the increased prevalence of G9P[8] (DÓRÓ et al., 2014; TAPISIZ et al., 2019).
Circulating and predominant genotypes have also changed in Australia (Table 2). G1P[8] was the 
predominant genotype in this country, but genotype G12P[8] followed by genotype G3P[8] has become 
the most frequent recently (DÓRÓ et al., 2014; ROCZO-FARKAS et al., 2017; ROCZO-FARKAS, CO-
WLEY ;BINES, 2019).
In the Orient, the most frequent strains are G1 and G9. In Israel, the predominant strain is G1P[8]; 
strain G3P[8] is the second most common strain in the country, but it has not been detected in other 
Eastern countries (MUHSEN et al., 2016). In Lebanon, G1P[8] along with G9P[8] was also prevalent a 
few years ago (Ali et al., 2016), whilst strains G1P[4] and G1P[6] prevail in Pakistan (DÓRÓ et al., 2014). 
In Saudi Arabia, the most common strain – G1P[8] – has declined, whereas strain G2P[4] has emerged 
and significantly increased in rotavirus cases (DÓRÓ et al., 2014; Al-Ayed et al., 2017).
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Currently in circulation References
AMERICA
SOUTH / NORTH
Argentina G1P[8] G2P[4] G12P[8]; G2P [4]; G9P[8]; G1P[8] Dóró et al., 2014; Mandile et al., 2014
Brazil G1P[8] G12P[8] G2P[4]; G9P[8]; G1P[8]; G12P[8]; G3P[8]
Dóró et al., 2014; 
Luchs and Timenetsky, 
2016; Patel et al., 2013; 
Carvalho-Costa et al., 
2019
Bolivia, Cuba, 
Chile, and Peru NA




Peláez-Carvajal et al., 
2014; Martínez et al., 
2010
Venezuela G1P[8] G2P[4] G2P[4]; G1P[8]; G9P[8]; G3P[8]; G2P[6] Vizzi et al., 2017
USA G3P[8] G12P[8] G1P[8]; G12P[12]; G9P[6]; G12P[8]; G3P[8]; G3P[9]  
Dóró et al., 2014; Mast 
et al., 2010; Wylie, 
Weinstock and Storch, 
2015; Bowen et al., 
2014
Canada G1P[8] G9P[8] G9P[8];G1P[8]; G2P[4]; G3P[8]; G3P[6]; G4P[8]; G9P[4] Chetrit el al., 2013
AFRICA
Cameroon G1P[8] G12P[8]
G1P[8]; G12P[6]; G12P[8]; G1P[6]; 
G3P[6]; G2P[4]; G8P[6]; G2P[6]; 
G3P[8]; 
Dóró et al., 2014; 
Ouermi et al., 2017
Ghana G1P[8] G2P[4] G2[6]; G3P[6]; G6P[6]; G2P[4]
Dóró et al., 2014; 
Ouermi et al., 2017; 
Agbemabiese et al., 
2016
Malawi G1P[8] G12P[6] G12P[6]; G2P[4]; G8P[6]; G12P[8] Ouermi et al., 2017; Nakagomi et al., 2017 
Nigeria G12P[8] G1P[8] G1[P8]; G3[P8]; G1P[5]; G6P[8]; G3P[6]
Ouermi et al., 2017; 
Motayo; Adeniji and 
Faneye, 2016
Kenya G1P[8] G9P[8] G9P[8]; G1P[8]; G2P[4]; G3P[8]; G4P[8]; G12P[8]
Dóró et al., 2014; 
Ouermi et al., 2017
Tunisia G2P[4] G1P[8] G3P[8]; G9P[8]; G4P[8]; G2P[4]; G12P[6]; G12P[8]
Dóró et al., 2014; 
Moussa et al.; 2016
ASIA
China G3P[8] G9P[8] G3P[8]; G9P[8]; G2P[4]; G1P[8] Dóró et al., 2014; Zhang et al., 2017
‣‣
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Japan G3P[8] G1P[8] G1P[8]; G2P[4]; G3P[8] Dóró et al., 2014; Fujii et al., 2019
South Korea G1P[8] G2P[4] G2P[4]; G1P[8]; G3P[8]; G4P[8]; G9P[8] Chung et al., 2015
Thailand NAa G1P[8] G2P[4]; G1P[8]; G3P[8] Dóró et al., 2014
Vietnam G3P[8] G1P[8] G2P[4]; G1P[8]; G3P[8]; G9P[19]; G10P[14] Do et al., 2017 
EUROPE / 
EURASIA
Austria NAa G2P[4] G2P[4]; G2P[4] Dóró et al., 2014
Belgium G1P[8] G2P[4] G3P[8]; G4P[8]; G9P[8]; G2P[4]; G1P[8] Pitzer et al., 2015
Greece G1P[8] G4P[8] G4P[8]; G1P[8]; G12P[8]; G3P[8]; G12P[6]
Dóró et al., 2014; 
Koukou et al., 2015
Hungary NAa G9P[8] G9P[8]; G2P[4]; G1P[8]; G4P[8] Dóró et al., 2014
India G1P[8] G9P[4] G1P[8]; G9P[4]; G2P[4]; G1P[6]
Gupta et al., 2019; 
Babji et al., 2018; 
Pradhan, Walimbe 
and Chitambar, 2016
Ireland G1P[8] G9P[4] G9P[4]; G1P[8]; G3P[4]; G2P[4]; G2P[8] Collins et al., 2015
Italy G1P[8] G2P[4] G1P[8]; G2P[4]; G9P[4]; G9P[8] Dóró et al., 2014
Romania G2P[4] G9P[8] G9P[8]; G4P[8]; G1P[8] Anca et al., 2014
Russia G4P[8] G1P[8] G4P[8]; G1P[8]; G3P[8]; G9P[8]; G2P[4]; G4P[4] Lobzin et al., 2017
Slovenia G1P[8] G4P[8] G4P[8]; G1P[8]; G2P[4] Steyer et al., 2014
Turkey G9P[8] G1P[8] G9P[8]; G1P[8]; G3P[8]; G2P[4] Dóró et al., 2014; Tapisiz et al., 2019
OCEANIA
Australia G1P[8] G12P[8] G12P[8]; G3P[8]; G1P[8]
Dóró et al., 2014; 




Israel G1P[8] G3P[8] G1P[8]; G3P[8]; G2P[4]; G4P[8]; G9P[8] Muhsen et al., 2016 
Lebanon G1P[8] G9P[8] G1P[8]; G9P[8]; G2P[4] Ali et al., 2016
Table 2 - Worldwide distribution of circulating and predominant rotavirus genotypes (cont.).
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Pakistan G1P[8] G1P[4] G1P[4]; G1P[8]; G1P[6]; G2P[4]; G2P[8]; G9P[8] Dóró et al., 2014
Saudi Arabia G1P[8] G2P[4] G2P[4]; G1P[8]; G1P[6]; G9P[8] Al-Ayed et al., 2017
a: not applicable
Source: Prepared by the authors.
Final considerations
The current global challenge regarding rotavirus infection is to ensure protection against the disease 
through immunization. Changes in the prevalence of circulating genotypes and re-emergence of serotypes 
have been reported worldwide. In addition, the virus can easily infect several animal species other than 
humans, as evidenced by reports of cross-infection of strains, which have served as warning that new 
virus genotypes have been generated.
Immunization helps to reduce health-related expenses and to reduce mortality due to the rotavirus, 
thus improving health indicators and significantly contributing to the promotion of health throughout 
the world.
The promotion of health should be inserted in the context of raising awareness of the importance of 
controlling infections caused by gastroenteric agents such as the rotavirus, which empowers populations. 
Inter-sectoral actions that encompass not only the health sector, but also all the socio-economic sector 
including the government, researchers, teachers, health agents, and communities are relevant. Such 
actions shall decrease health-related expenditures and reduce mortality caused by the rotavirus, thereby 
improving health indicators and promoting health around the world.
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